Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies. © 2005 Cancer Research.
CITATION STYLE
Bartlett, J. B., Tozer, A., Stirling, D., & Zeldis, J. B. (2005, September 19). Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602774
Mendeley helps you to discover research relevant for your work.